ArticleAmerican journal of cancer research2025
Effect of antihypertensive drugs on survival in patients with non-small cell lung cancer on epidermal growth factor receptor inhibitors.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) show efficacy against non-small cell lung cancer (NSCLC) in patients with EGFR mutations. However, the impact of antihypertensive medications, particularly beta-blockers (BBs) and renin-angiotensin system blockers (RASBs), on survival outcomes in this population remains controversial. We evaluated the effects of BBs and RASBs on progression-free survival (PFS) and overall survival (OS) in patients with NSCLC receiving EGFR-TKIs. This retrospective study included patients diagnosed with NSCLC who received EGFR-TKIs at a regional teaching hospital in Taiwan between 2009 and 2023. Overall, 308 patients were categorized into groups: EGFR-TKIs only (n=175), BBs(+)/EGFR-TKIs(+) (n=70), and RASBs(+)/EGFR-TKIs(+) (n=63). Primary and secondary outcomes were PFS and OS, respectively. Multivariate Cox proportional-hazards models were used for analysis. Median PFS was 7.79, 11.74, and 10.42 months in the EGFR-TKIs only, BBs(+)/EGFR-TKIs(+), and RASBs(+)/EGFR-TKIs(+) groups, respectively (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.